The Process
Four stages.
Months compressed into minutes.
Vainture Signal — commercialization analysis at the speed of decision. Every idea runs through the same six-dimension evaluation and earns a Signal Score backed by named markets, named competitors, named investors, and named funding sources.
Intake
Scientists submit ideas through a structured form, or paste existing IP — a patent abstract, an invention disclosure, a patent number. Two paths in. Same evaluation pipeline.
Evaluate
The AI runs a multi-dimensional commercialization analysis with live web search. Real market data. Real competitors. Real investors. Real funding sources. Six dimensions, all scored.
Form
Every evaluation produces a Vainture Signal Report — executive summary, market opportunity, competitive landscape, regulatory pathway, named investors, named partners, named funding programs, ranked next steps. Proceed, pivot, or kill — each verdict comes with the evidence behind it.
Launch
The portfolio dashboard surfaces the highest-scoring opportunities for institutional decision-making. Investors review pre-evaluated pipelines as part of due diligence. Resources flow to ideas with evidence behind them.
How we evaluate
Six dimensions. One overall score.
Every evaluation is scored across the six dimensions that determine whether an innovation can become a venture. Weights are fixed and transparent.
Market Opportunity
25%Total addressable market, serviceable market, growth rate, key drivers and barriers. Real numbers from current sources, not training data.
Competitive Landscape
20%Named competitors with their approach, differentiation analysis, competitive risk assessment. We name companies, not categories.
Regulatory Pathway
15%Likely FDA pathway, estimated timeline and cost, expedited options (Breakthrough, Fast Track, Orphan), key regulatory risks.
Investor Landscape
15%Named VC firms, family offices, and strategic investors that have funded comparable companies. Recent deals, typical check sizes, stages.
Strategic Partners
15%Named pharma, biotech, medtech, and device companies that would be logical licensing partners or acquirers. Recent deal activity.
Public Funding
10%Named NIH FOAs, CPRIT programs, DARPA, BARDA, NSF, foundation grants, SBIR/STTR. Award amounts and deadlines where available.
Why this is different
We are not an incubator. We are not a tech transfer office.
vs. Traditional Incubators
Incubators are biased toward saying yes — their cohort fills regardless of idea quality. Vainture Signal scores every idea against the same evidence threshold so the institution funds the ones that clear it.
vs. Tech Transfer Offices
TTOs are over-stretched and under-resourced. A small team manually reviews every disclosure. Vainture lets that team focus on the few ideas that actually have commercial potential.
vs. Manual Consulting
A senior commercialization analyst takes weeks to produce one report. Vainture produces the same structured output in minutes — and runs it across the entire portfolio.
See Vainture Signal in action.
We are running live demonstrations for research institutions and venture firms. Tell us about your portfolio, and we will walk you through the platform.
Request a Demo